According to the Trial of PARP Inhibition in Prostate Cancer (TOPARP)‐A and TOPARP‐B, the PARP inhibitors have achieved great progress in the treatment of mCRPC patients who carry HRR deficiency.32, 33. This evidence concerns the gene PARP1 and Familial prostate cancer.